About The Peptide Woman

The unfinished entry

The primary-care management gap makes an impatient reader of me. The review describing limited drug efficacy gives that impatience a necessary complication. Better attention to women's sexual health has to include room for an unexciting or unwelcome answer about a medicine.

The moment when sympathy is tempted to become advocacy for a product interests me. Sympathy can do something more useful: insist that a concern receives a hearing, then stay attentive when the proposed response turns out to have limits.

The record study covers different sexual dysfunction diagnoses; the bremelanotide trials enrolled premenopausal women with HSDD. Moving directly from that gap to this medicine skips the difference between the populations. That difference is especially easy to lose when an argument begins with a wish for better care.

Another temptation is to treat a prescription as proof that a concern has been heard. I want a sequel that describes a response worth having, including a response that does not involve medication. That is a preference about care, rather than an inference that any particular unrecorded case in the study was mishandled. The gap leaves individual stories unresolved, and the medicine cannot supply their endings.

The name and the limits

The Peptide Woman names this publication. Its concern is the published research on women's sexual health. It offers no clinical services, products or appointments and operates no health business.

Nothing here provides medical advice, an assessment of someone's symptoms or a treatment plan. A private decision about care requires attention to the person whose health is at stake, beyond anything these pages can provide. Personal medical histories have no place to be submitted here.